XML 96 R82.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Collaborative and Other Relationships Textual (Details) |  |  |  |  | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Nov. 03, 2023 USD ($) payment | Sep. 15, 2021 USD ($) | Nov. 05, 2019 USD ($) | Sep. 30, 2013 USD ($) | Aug. 31, 2020 USD ($) | Sep. 30, 2018 USD ($) dose | Dec. 31, 2022 USD ($) dose | Dec. 31, 2021 USD ($) dose | Dec. 31, 2019 USD ($) dose | Nov. 30, 2023 | Mar. 31, 2015 USD ($)
U.S. Department of Health and Human Services, net |  |  |  |  |  |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement contract value |  |  |  |  |  | $ 34,660,000 |  |  |  |  |
Contract term (year) |  |  |  |  |  | 5 years |  |  |  |  |
U.S. Department of Health and Human Services, net | RAPIVAB |  |  |  |  |  |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |  |  |  |  |  |  |  |  |  |
Maximum number of products, doses | dose |  |  |  |  |  | 50,000 |  |  |  |  |
Number of product delivered, doses | dose |  |  |  |  |  |  | 49,980 |  | 20,000 |  |
Proceeds from collaborators |  |  |  |  |  |  | $ 13,864,000 | $ 6,918,000 | $ 13,864,000 |  |
Number of additional products, doses | dose |  |  |  |  |  |  | 20,000 | 9,980 |  |  |
Torii Pharmaceutical Co |  |  |  |  |  |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |  |  |  |  |  |  |  |  |  |
Contract with customer, liability |  |  | $ 22,000,000 |  |  |  |  |  |  |  |
Potential milestone payments receivable if regulatory approval before december 31, 2021 |  |  | $ 15,000,000 |  |  |  |  |  |  |  |
Maximum customary reduction on royalty rate |  |  | 50.00% |  |  |  |  |  |  |  |
Royalty payments receivable, expiration term from first commercial (year) |  |  | 10 years |  |  |  |  |  |  |  |
Torii Pharmaceutical Co | Minimum |  |  |  |  |  |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |  |  |  |  |  |  |  |  |  |
Royalty rate if maintains sakigake designation |  |  | 20.00% |  |  |  |  |  |  | 20.00% |
Torii Pharmaceutical Co | Maximum |  |  |  |  |  |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |  |  |  |  |  |  |  |  |  |
Royalty rate if maintains sakigake designation |  |  | 40.00% |  |  |  |  |  |  | 80.00% |
Clearside Biomedical, Inc. |  |  |  |  |  |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |  |  |  |  |  |  |  |  |  |
License agreement, upfront payment | $ 5,000,000 |  |  |  |  |  |  |  |  |  |
Number of milestone payments | payment | 3 |  |  |  |  |  |  |  |  |  |
Royalty payment, number of tiers | payment | 3 |  |  |  |  |  |  |  |  |  |
Clearside Biomedical, Inc. | Annual Net Sales Of $2 Million |  |  |  |  |  |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |  |  |  |  |  |  |  |  |  |
Annual global net sales | $ 2,000,000,000 |  |  |  |  |  |  |  |  |  |
Clearside Biomedical, Inc. | Annual Net Sales Greater Than $1.5 Million |  |  |  |  |  |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |  |  |  |  |  |  |  |  |  |
Annual global net sales | 1,500,000,000 |  |  |  |  |  |  |  |  |  |
Clearside Biomedical, Inc. | Maximum |  |  |  |  |  |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments payable | 30,000,000 |  |  |  |  |  |  |  |  |  |
Potential milestone payments payable if regulatory approval before milestone | $ 47,500,000 |  |  |  |  |  |  |  |  |  |
Base Contract |  |  |  |  |  |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |  |  |  |  |  |  |  |  |  |
Government contract receivable |  |  |  |  |  |  |  |  |  |  | $ 16,265,000
Additional Development Options |  |  |  |  |  |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |  |  |  |  |  |  |  |  |  |
Government contract receivable |  |  |  |  |  |  |  |  |  |  | 22,855,000
ASPRBARDA Contract |  |  |  |  |  |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |  |  |  |  |  |  |  |  |  |
Government contract receivable |  |  |  |  |  |  |  |  |  |  | $ 39,120,000
Proceeds from awards for research and development contracts |  |  |  |  |  |  | $ 20,574,000 |  |  |  |
National Institute of Allergy and Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |  |  |  |  |  |  |  |  |  |
Receivable from awards for research and development contracts |  | $ 47,315,000 |  | $ 45,931,000 |  |  |  |  |  |  |
Potential aggregate maximum amount of funding |  |  |  |  | $ 43,908,000 |  |  |  |  |  |
Collaborative agreement contract value |  |  |  |  | $ 6,326,000 |  |  |  |  |  |

X
- Definition CollaborativeAgreementContractCovenantMaximumAmountOfFunding + References No definition available. + Details
Name: | bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement Contract Value + References No definition available. + Details
Name: | bcrx_CollaborativeAgreementContractValue
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition ContractTerm + References No definition available. + Details
Name: | bcrx_ContractTerm
Namespace Prefix: | bcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts + References No definition available. + Details
Name: | bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License Agreement, Annual Global Net Sales + References No definition available. + Details
Name: | bcrx_LicenseAgreementAnnualGlobalNetSales
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement, Number of Milestone Payments + References No definition available. + Details
Name: | bcrx_LicenseAgreementNumberOfMilestonePayments
Namespace Prefix: | bcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Royalty Payment, Number of Tiers + References No definition available. + Details
Name: | bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers
Namespace Prefix: | bcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Upfront Payment + References No definition available. + Details
Name: | bcrx_LicenseAgreementUpfrontPayment
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition MaximumCustomaryReductionOnRoyaltyRate + References No definition available. + Details
Name: | bcrx_MaximumCustomaryReductionOnRoyaltyRate
Namespace Prefix: | bcrx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Maximum Number Of Products Permitted To Be Obtained, Doses + References No definition available. + Details
Name: | bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses
Namespace Prefix: | bcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Additional Products, Doses + References No definition available. + Details
Name: | bcrx_NumberOfAdditionalProductsDoses
Namespace Prefix: | bcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Product Delivered, Doses + References No definition available. + Details
Name: | bcrx_NumberOfProductDeliveredDoses
Namespace Prefix: | bcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential Milestone Payments Payable + References No definition available. + Details
Name: | bcrx_PotentialMilestonePaymentsPayable
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential Milestone Payments Payable If Regulatory Approval Before Milestone + References No definition available. + Details
Name: | bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential Milestone Payments Receivable If Regulatory Approval Before December 31, 2021 + References No definition available. + Details
Name: | bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition ProceedsFromAwardsForResearchAndDevelopmentContracts + References No definition available. + Details
Name: | bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty Payments Receivable Expiration Term From First Commercial + References No definition available. + Details
Name: | bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial
Namespace Prefix: | bcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Rate + References No definition available. + Details
Name: | bcrx_RoyaltyRate
Namespace Prefix: | bcrx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of receivables that are derived from government contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482312/912-310-45-1 + Details
Name: | us-gaap_GovernmentContractReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bcrx_RAPIVABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bcrx_ClearsideBiomedicalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOf2MillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesGreaterThan15MillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |